NASDAQ:AURA Aura Biosciences (AURA) Stock Price, News & Analysis $11.39 -0.26 (-2.23%) (As of 10/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Aura Biosciences Stock (NASDAQ:AURA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$11.01▼$11.7250-Day Range$7.39▼$11.7452-Week Range$5.99▼$12.38Volume201,422 shsAverage Volume176,546 shsMarket Capitalization$564.29 millionP/E RatioN/ADividend YieldN/APrice Target$23.00Consensus RatingBuy Company OverviewAura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Aura Biosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks76th Percentile Overall ScoreAURA MarketRank™: Aura Biosciences scored higher than 76% of companies evaluated by MarketBeat, and ranked 263rd out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingAura Biosciences has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAura Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Aura Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Aura Biosciences are expected to decrease in the coming year, from ($1.70) to ($2.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aura Biosciences is -6.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aura Biosciences is -6.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAura Biosciences has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aura Biosciences' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.69% of the float of Aura Biosciences has been sold short.Short Interest Ratio / Days to CoverAura Biosciences has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Aura Biosciences has recently decreased by 12.21%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAura Biosciences does not currently pay a dividend.Dividend GrowthAura Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.69% of the float of Aura Biosciences has been sold short.Short Interest Ratio / Days to CoverAura Biosciences has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Aura Biosciences has recently decreased by 12.21%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment0.37 News SentimentAura Biosciences has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Aura Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for AURA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows6 people have added Aura Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Aura Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $675,952.00 in company stock.Percentage Held by InsidersOnly 5.40% of the stock of Aura Biosciences is held by insiders.Percentage Held by Institutions96.75% of the stock of Aura Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aura Biosciences' insider trading history. AURA Stock News HeadlinesAura Biosciences, Inc. (NASDAQ:AURA) CFO Sells $302,325.93 in StockOctober 22 at 4:13 AM | insidertrades.comLos Pinos Elisabet De Sells 24,992 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) StockOctober 19, 2024 | insidertrades.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 23, 2024 | Porter & Company (Ad)Aura Biosciences, Inc. (NASDAQ:AURA) CTO Sells $72,722.55 in StockOctober 17, 2024 | insidertrades.com3 Small-Cap Stocks Ready to Deliver Significant GrowthSmall-cap firms will have an easier time borrowing money for growth in a lower-interest-rate environment; these are a few companies poised for a breakout.October 10, 2024 | marketbeat.comJulie B. Feder Sells 25,131 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) StockOctober 23 at 5:06 AM | americanbankingnews.comBrokerages Set Aura Biosciences, Inc. (NASDAQ:AURA) Price Target at $23.00October 23 at 2:52 AM | americanbankingnews.comPromising Phase 1 Results and Strong Safety Profile of Bel-sar Support Buy Rating for Aura Biosciences IncOctober 22 at 6:46 AM | markets.businessinsider.comSee More Headlines AURA Stock Analysis - Frequently Asked Questions How have AURA shares performed this year? Aura Biosciences' stock was trading at $8.86 at the start of the year. Since then, AURA stock has increased by 28.6% and is now trading at $11.39. View the best growth stocks for 2024 here. How were Aura Biosciences' earnings last quarter? Aura Biosciences, Inc. (NASDAQ:AURA) posted its earnings results on Thursday, August, 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.04. When did Aura Biosciences IPO? Aura Biosciences (AURA) raised $81 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 5,400,000 shares at a price of $14.00-$16.00 per share. Who are Aura Biosciences' major shareholders? Top institutional shareholders of Aura Biosciences include Regency Capital Management Inc. DE (1.35%), SG Americas Securities LLC (0.04%) and Exchange Traded Concepts LLC (0.03%). Insiders that own company stock include Matrix Capital Management Comp, Los Pinos Elisabet De, Julie B Feder, Cadmus Rich and Rosch Mark De. View institutional ownership trends. How do I buy shares of Aura Biosciences? Shares of AURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aura Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aura Biosciences investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/08/2024Today10/22/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AURA CUSIPN/A CIK1501796 Webwww.aurabiosciences.com Phone617-500-8864FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$24.00 Low Stock Price Target$22.00 Potential Upside/Downside+101.9%Consensus RatingBuy Rating Score (0-4)3.29 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-41.49% Return on Assets-36.34% Debt Debt-to-Equity RatioN/A Current Ratio18.54 Quick Ratio18.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.58 per share Price / Book2.49Miscellaneous Outstanding Shares49,543,000Free Float46,927,000Market Cap$564.29 million OptionableNot Optionable Beta0.37 This page (NASDAQ:AURA) was last updated on 10/23/2024 by MarketBeat.com Staff From Our Partners[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredAre You Holding the Winning Hand in the Copper Market?Are You Holding the Winning Hand in the Copper Market?Market JAR | Sponsored$20 = Ounce of Gold?I've discovered a way to get exposure to MORE than an ounce of gold... for under $20. It's not bullion. It'...Monument Traders Alliance | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored[INSIDE] The $16 “AI stock” set to soarThere's one tiny firm that's providing the backbone of the entire AI sector. It's at the heart of $85 trill...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Aura Biosciences, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.